AI주식인사이트AI Stock Insight
B

HK이노엔

195940KOSDAQ

57.0 / 100

Reference Date: 2026-10-23

Financial Score27.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 12.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HK Inoent is a pharmaceutical company primarily engaged in ETC (Specialty Pharmaceuticals) and H&B (Health & Beauty) businesses, achieving sales of 1.632 trillion KRW and operating profit of 110.9 billion KRW in 2025 through key products like K-Cap and H&B items such as Condition. Established in 1984, the company expanded through the acquisition of Hanil Pharm in 2006 and Hanacolma in 2018, focusing on R&D and global market expansion.

Number of Employees

1,723people

Average Salary

84.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
12.78Industry Average 15.005.0Point

In line with industry avg

PBR
0.73Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
5.87Industry Average 8.002.5Point

Below industry avg

Debt Ratio
13.25Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲29.8% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 5.0% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 34,150Won52-week high 57,60052-week low 34,150
1-month return1.0Point

1m -12.77% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral결산실적공시예고2026-10-22
  • Neutral주식등의대량보유상황보고서(약식)2026-10-02